2024/08/30 08:08:28 | |
---|---|
Price | |
444.95 EUR | |
Difference | 0.91% (4.00) |
ISIN | US92532F1003 |
Symbol | VRTX |
Exchange | Berlin |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 114,923 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 444.80 EUR (23) |
Ask (Ask size) | 446.75 EUR (23) |
Open | 444.95 EUR |
High | 444.95 EUR |
Low | 444.95 EUR |
Close (prev. day) | 440.95 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/08/12 |
![]() |
Global Equity Ratings |
![]() |
2024/07/24 |
![]() |
Global Equity Ratings |
![]() |
2024/07/12 |
![]() |
Global Equity Ratings |
![]() |
2024/06/21 |
![]() |
Global Equity Ratings |
![]() |
2024/06/14 |
![]() |
Global Equity Ratings |
![]() |
2024/08/30 08:08:28 | |
---|---|
Price | |
444.95 EUR | |
Difference | 0.91% (4.00) |
ISIN | US92532F1003 |
Symbol | VRTX |
Exchange | Berlin |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 114,923 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | 444.80 EUR (23) |
Ask (Ask size) | 446.75 EUR (23) |
Open | 444.95 EUR |
High | 444.95 EUR |
Low | 444.95 EUR |
Close (prev. day) | 440.95 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | +12.16% | +35.95% | +161.88% |
Perf (abs.) | +47.80 | +116.60 | +272.57 |
Beta | 0.43 | 0.56 | 0.60 |
Volatility | 19.79 | 21.55 | 25.62 |
Ø price 5 days | Ø volume 5 days (pcs.) | 432.55 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 441.26 EUR (1) |
Ø price 100 days | Ø volume 100 days (pcs.) | 421.92 EUR (0) |
Ø price 250 days | Ø volume 250 days (pcs.) | 385.34 EUR (1) |
YTD High | date | 465.20 EUR (2024/08/02) |
YTD Low | date | 364.35 EUR (2024/04/11) |
52 Weeks High | date | 465.20 EUR (2024/08/02) |
52 Weeks Low | date | 315.30 EUR (2023/11/29) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2024/08/30 | 09:04 | 443.70 EUR | 0.00 | 2 |
Vienna Stock Exchange | 2024/08/30 | 13:00 | 445.65 EUR | 0.00 | 3 |
Tradegate | 2024/08/30 | 14:29 | 446.80 EUR | 0.06 | 14 |
Stuttgart | 2024/08/30 | 08:10 | 445.05 EUR | 0.00 | 1 |
Nasdaq | 2024/08/29 | 22:00 | 493.35 USD | 348.97 | 24,641 |
Munich | 2024/08/30 | 08:00 | 444.85 EUR | 0.00 | 1 |
London Stock Exchange | 2024/08/12 | 16:16 | 464.455 USD | 0.00 | 1 |
Hanover | 2024/08/30 | 08:01 | 444.95 EUR | 0.00 | 1 |
Hamburg | 2024/08/30 | 13:16 | 446.60 EUR | 0.00 | 2 |
Frankfurt | 2024/08/30 | 08:00 | 444.45 EUR | 0.00 | 1 |
Euronext Milan MTF Trading After Hours | 2024/07/04 | 18:14 | 448.30 EUR | 0.00 | 1 |
Euronext Milan MTF Global Equity Market | 2024/08/29 | 17:44 | 448.70 EUR | 0.00 | 3 |
Duesseldorf | 2024/08/30 | 12:30 | 445.00 EUR | 0.00 | 3 |
Berlin | 2024/08/30 | 08:08 | 444.95 EUR | 0.00 | 1 |
VERTEX PHARMACEUTICALS INC. |
- - |
50 Northern Avenue - 02210 Boston |
Telefon: +1-617-341-6100 |
Fax: + |
E-mail: mediainfo@vrtx.com |
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA. |
Jeffrey Leiden | Chairman of Board of Directors |
Alan Garber | Member of Board of Directors |
Jennifer Schneider | Member of Board of Directors |
Sangeeta Bhatia | Member of Board of Directors |
Bruce Sachs | Member of Board of Directors |
Diana McKenzie | Member of Board of Directors |
Lloyd Carney | Member of Board of Directors |
Michel Lagarde | Member of Board of Directors |
Nancy Thornberry | Member of Board of Directors |
Suketu Upadhyay | Member of Board of Directors |
Reshma Kewalramani | Chairman of Managing Board |
David Altshuler | Member of Executive Committee |
Amit K. Sachdev | Member of Executive Committee |
Bastiano Sanna | Member of Executive Committee |
Carmen Bozic | Member of Executive Committee |
Charles F. Wagner | Member of Executive Committee |
E. Morrey Atkinson | Member of Executive Committee |
Jonathan Biller | Member of Executive Committee |
Nia Tatsis | Member of Executive Committee |
Stuart A. Arbuckle | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended), citizen/resident of Australia, Canada, Great Britain and Japan. For this reason, the distribution or redistribution of the information, materials and products into United States, Australia, Canada, Great Britain and Japan or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited.
The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.
(iV) It is no consumer.